Dr. Sadasivan Vidyasagar (shown left), Assistant Professor in the Department of Radiation Oncology, serves as the principal inventor with a UF research team that developed enterade®, a combination of proprietary amino acid blends to help patients with GI issues related to cancer or chronic GI disease.
“We’ve selected amino acids based on functional alterations associated with diseases rather than going after specific diseases,” said Dr. Vidyasagar.
University of Florida startup Entrinsic Health Solutions Inc. (EHS), a health sciences company, recently announced that it has entered into a partnership with Nestlé Health Science (NHSc) to provide for a worldwide commercial license and supply agreement for NHSc will take over the global commercialization of enterade® following the results of a clinical study of neuroendocrine tumor (NET) patients.
The prospective Phase II study of enterade® in NET and carcinoid syndrome patients with quality-of-life limiting diarrhea has been initiated and is expected to conclude in 2019. This new study will assess how enterade® helps patients absorb and retain fluids. A pilot clinical study conducted at the University of Kentucky Markey Cancer Center demonstrated that daily consumption of enterade® leads to a marked improvement in patient’s overall quality of life. These results were published in the 2018 ASCO Annual Meeting Proceedings.
Read more about the partnership on the UF News website.